BioSpace News Archive

Yield10 Bioscience, Inc., an agricultural bioscience company, announced the closing of its previously announced public offering of 5,750,000 units at a public offering price of $0.65 per unit.

As orthopaedic medicine continues to advance through innovation, research and evidence-based medicine, the complexities and unknowns about newer treatments such as orthobiologics, may leave patients wondering if it is a viable treatment option for them.

Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced the speaker lineup for their Quantitative Systems Pharmacology (QSP) Summit occurring Thursday, October 12, 2023 in Cambridge, MA.

MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the second quarter ended June 30, 2023, and provided a corporate update.

Sarnova, a leading specialty distributor of healthcare products and services, announced recent leadership changes that will help drive accelerated growth and expansion across all of Sarnova’s family of companies.

Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.67 billion for the third quarter ended July 31, 2023, a decrease of 2.7% compared to the third quarter of 2022 and a decrease of 2.3% on a core(1) basis.

PAVmed Inc. (NASDAQ: PAVM, PAVMZ) (“PAVmed” or the “Company”) today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) (“Lucid”) and Veris Health Inc. (“Veris”), and presented financial results for the Company for the three and six months ended June 30, 2023.

AN2 Therapeutics, Inc. announced the pricing of an underwritten offering of 7,777,778 shares of its common stock.

Transcenta Holding Limited (“Transcenta”) (HKEX: 06628) announces that it is going to present three posters highlighting study results from ongoing trials related to Osemitamab (TST001) at the 2023 European Society of Medical Oncology (ESMO) Congress.

Sensible Diagnostics, Inc. has announced it has been selected by the Rapid Acceleration of Diagnostics Tech program launched by the National Institutes of Biomedical Imaging and Bioengineering, part of the National Institutes of Health.